Childhood constipation: Finally something is moving!

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 1, 2016, Pages 141-155

  Koppen, Ilan J N ^a,b   Di Lorenzo, Carlo ^b   Saps, Miguel ^b   Dinning, Phil G ^c   Yacob, Desale ^b   Levitt, Marc A ^d   Benninga, Marc A ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c FLINDERS UNIVERSITY   (Australia)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Anorectal manometry; Children; Colonic manometry; constipation; Electrical stimulation; Sacral neurostimulation

Indexed keywords

ELOBIXIBAT; GHRELIN RECEPTOR; LINACLOTIDE; LUBIPROSTONE; PREBIOTIC AGENT; PROBIOTIC AGENT; RELAMORELIN; SEROTONIN AGONIST; SYNBIOTIC AGENT; CHENODEOXYCHOLIC ACID; CHLORIDE CHANNEL STIMULATING AGENT; DIPEPTIDE; LAXATIVE; PEPTIDE; SEROTONIN RECEPTOR AFFECTING AGENT; THIAZEPINE DERIVATIVE;

ALTERNATIVE MEDICINE; ANORECTAL PRESSURE; BILE ACID METABOLISM; CLINICAL EFFECTIVENESS; COLON LAVAGE; COLONIC MANOMETRY; CONSTIPATION; DIET THERAPY; DIETARY FIBER; DIGESTIVE THERAPEUTIC DEVICE; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; HYPNOTHERAPY; INTESTINE FLORA; INTESTINE RESECTION; INTESTINE TRANSIT TIME; MANAGED CARE; MANOMETRY; MEDICAL HISTORY; MINDFULNESS; NONHUMAN; PHYSICAL EXAMINATION; REVIEW; SACRAL NERVE STIMULATION; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; VIBRANT CAPSULE; YOGA; ADMINISTRATION AND DOSAGE; AGONISTS; ANAL CANAL; ANAMNESIS; CHILD; COLON; DIETARY SUPPLEMENT; ELECTRODE IMPLANT; GASTROINTESTINAL TRANSIT; LAVAGE; PATHOPHYSIOLOGY; RECTUM; TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION;

ANAL CANAL; CATHARTICS; CHENODEOXYCHOLIC ACID; CHILD; CHLORIDE CHANNEL AGONISTS; COLON; CONSTIPATION; DIETARY FIBER; DIETARY SUPPLEMENTS; DIPEPTIDES; ELECTRODES, IMPLANTED; GASTROINTESTINAL TRANSIT; HUMANS; LUBIPROSTONE; MANOMETRY; MEDICAL HISTORY TAKING; PEPTIDES; PHYSICAL EXAMINATION; RECEPTORS, GHRELIN; RECTUM; SEROTONIN AGENTS; THERAPEUTIC IRRIGATION; THIAZEPINES; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION;

EID: 84945209045     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1098533     Document Type: Review

References (130)

1. Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: Evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58 (2):258-274.
2. Mugie SM, Di Lorenzo C, Benninga MA. Constipation in childhood. Nat Rev Gastroenterol Hepatol. 2011;8 (9):502-511.
3. Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: Child/adolescent. Gastroenterology. 2006;130(5):1527-1537.
4. Saps M, Nichols-Vinueza DX, Mintjens S, et al. Construct validity of the pediatric Rome III criteria. J Pediatr Gastroenterol Nutr. 2014;59(5):577-581.
5. Koppen IJN, Lammers LA, Benninga MA, et al. Management of functional constipation in children: Therapy in practice. Paediatr Drugs. 2015. [Epub ahead of print]. DOI:10.1007/s40272-015-0142-4.
6. Lane MM, Czyzewski DI, Chumpitazi BP, et al. Reliability and validity of a modified Bristol Stool Form Scale for children. J Pediatr. 2011;159(3):437-441.e1.
7. Van Der Plas RN, Benninga MA, Redekop WK, et al. How accurate is the recall of bowel habits in children with defaecation disorders? Eur J Pediatr. 1997;156(3):178-181.
8. Self MM, Williams AE, Czyzewski DI, et al. Agreement between prospective diary data and retrospective questionnaire report of abdominal pain and stooling symptoms in children with irritable bowel syndrome. Neurogastroenterol Motil. 2015;27(8):1110-1119.
9. Kim ER, Rhee P-L. How to interpret a functional or motility test-colon transit study. J Neurogastroenterol Motil. 2012;18(1):94-99.
10. Arhan P, Devroede G, Jehannin B, et al. Segmental colonic transit time. Dis Colon Rectum. 1981;24(8):625-629.
11. Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40-47.
12. Bouchoucha M, Devroede G, Arhan P, et al. What is the meaning of colorectal transit time measurement? Dis Colon Rectum. 1992;35(8):773-782.
13. Southwell BR, Clarke MCC, Sutcliffe J, et al. Colonic transit studies: Normal values for adults and children with comparison of radiological and scintigraphic methods. Pediatr Surg Int. 2009;25 (7):559-572.
14. Belkind-Gerson J, Tran K, Di Lorenzo C. Novel techniques to study colonic motor function in children. Curr Gastroenterol Rep. 2013;15(8):335.
15. Mugie SM, Perez ME, Burgers R, et al. Colonic manometry and colonic scintigraphy as a diagnostic tool for children with severe constipation. J Pediatr Gastroenterol Nutr. 2013;57(5):598-602.
16. Green AD, Belkind-Gerson J, Surjanhata BC, et al. Wireless motility capsule test in children with upper gastrointestinal symptoms. J Pediatr. 2013;162(6):1181-1187.
17. Camilleri M, Thorne NK, Ringel Y, et al Wireless pH-motility capsule for colonic transit: Prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil. 2010;22 (8):874-82, e233.
18. Rao SSC, Kuo B, McCallum RW, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol. 2009;7 (5):537-544.
19. Ambartsumyan L, Rodriguez L, Morera C, et al. Longitudinal and radial characteristics of intra-anal pressures in children using 3D high-definition anorectal manometry: New observations. Am J Gastroenterol. 2013;108(12):1918-1928.
20. Dinning PG, Carrington EV, Scott SM. The use of colonic and anorectal highresolution manometry and its place in clinical work and in research. Neurogastroenterol Motil. 2015. [Epub ahead of print]. DOI:10.1111/nmo.12632.
21. Dinning PG, Di Lorenzo C. Colonic dysmotility in constipation. Best Pract Res Clin Gastroenterol. 2011;25(1):89-101.
22. Stanton MP, Hutson JM, Simpson D, et al. Colonic manometry via appendicostomy shows reduced frequency, amplitude, and length of propagating sequences in children with slow-transit constipation. J Pediatr Surg. 2005;40 (7):1138-1145.
23. King SK, Catto-Smith AG, Stanton MP, et al. 24-hour colonic manometry in pediatric slow transit constipation shows significant reductions in antegrade propagation. Am J Gastroenterol. 2008;103 (8):2083-2091.
24. Van Den Berg MM, Hogan M, Caniano DA, et al. Colonic manometry as predictor of cecostomy success in children with defecation disorders. J Pediatr Surg. 2006;41(4):730-6; discussion 730-6.
25. Liem O, Burgers RE, Connor FL, et al. Solid-state vs water-perfused catheters to measure colonic high-amplitude propagating contractions. Neurogastroenterol Motil. 2012;24(4):345-e167.
26. Cook IJ, Furukawa Y, Panagopoulos V, et al. Relationships between spatial patterns of colonic pressure and individual movements of content. Am J Physiol Gastrointest Liver Physiol. 2000;278(2): G329-41.
27. Bampton PA, Dinning PG, Kennedy ML, et al. Spatial and temporal organization of pressure patterns throughout the unprepared colon during spontaneous defecation. Am J Gastroenterol. 2000;95 (4):1027-1035.
28. Di Lorenzo C, Flores AF, Reddy SN, et al. Use of colonic manometry to differentiate causes of intractable constipation in children. J Pediatr. 1992;120 (5):690-695.
29. Dinning PG, Wiklendt L, Maslen L, et al. Quantification of in vivo colonic motor patterns in healthy humans before and after a meal revealed by high-resolution fiber-optic manometry. Neurogastroenterol Motil. 2014;26 (10):1443-1457.
30. Dinning PG, Wiklendt L, Gibbins I, et al Low-resolution colonic manometry leads to a gross misinterpretation of the frequency and polarity of propagating sequences: Initial results from fiber-optic high-resolution manometry studies. Neurogastroenterol Motil. 2013;25(10): E640-e649.
31. Dinning PG, Wiklendt L, Maslen L, et al. Colonic motor abnormalities in slow transit constipation defined by high resolution, fibre-optic manometry. Neurogastroenterol Motil. 2015;27(3):379-388.
32. Giorgio V, Borrelli O, Smith VV, et al. High-resolution colonic manometry accurately predicts colonic neuromuscular pathological phenotype in pediatric slow transit constipation. Neurogastroenterol Motil. 2013;25(1):70-78.
33. El-Chammas KI, Tipnis NA, Simpson PM, et al. Colon high-resolution manometry: Using pressure topography plots to evaluate pediatric colon motility. J Pediatr Gastroenterol Nutr. 2014;59(4):500-504.
34. Anderson JW, Baird P, Davis RH, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67(4):188-205.
35. Morais MB, Vítolo MR, Aguirre AN, et al. Measurement of low dietary fiber intake as a risk factor for chronic constipation in children. J Pediatr Gastroenterol Nutr. 1999;29(2):132-135.
36. Tabbers MM, Benninga MA. Constipation in children: Fibre and probiotics. [Internet]. BMJ Clin Evid. 2015;03:303. Available from: Http://www.ncbi.nlm.nih.gov/pubmed/25758093
37. Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics. 2012;129 (5):950-960.
38. West CE, Jenmalm MC, Prescott SL. The gut microbiota and its role in the development of allergic disease: A wider perspective. Clin Exp Allergy. 2014;45 (1):43-53.
39. West CE, Renz H, Jenmalm MC, et al. The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135 (1):3-13.
40. Zhu L, Liu W, Alkhouri R, et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics. 2014;46(18):679-686.
41. Triantafyllou K, Chang C, Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil. 2014;20(1):31-40.
42. Jahng J, Jung IS, Choi EJ, et al. The effects of methane and hydrogen gases produced by enteric bacteria on ileal motility and colonic transit time. Neurogastroenterol Motil. 2012;24 (2):185-90, e92.
43. Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290(6): G1089-95.
44. Patel R, DuPont HL. New approaches for bacteriotherapy: Prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015;60(suppl 2):S108-S121.
45. Dimidi E, Christodoulides S, Fragkos KC, et al. The effect of probiotics on functional constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(4):1075-1084.
46. Gordon M, Naidoo K, Akobeng AK, et al. Cochrane review: Osmotic and stimulant laxatives for the management of childhood constipation (Review). Evid Based Child Health. 2013;8(1):57-109.
47. Michaud L, Lamblin M-D, Mairesse S, et al. Outcome of functional constipation in childhood: A 10-year follow-up study. Clin Pediatr (Phila). 2009;48 (1):26-31.
48. Van Ginkel R, Reitsma JB, Büller HA, et al. Childhood constipation: Longitudinal follow-up beyond puberty. Gastroenterology. 2003;125(2):357-363.
49. Bongers MEJ, Van Wijk MP, Reitsma JB, et al. Long-term prognosis for childhood constipation: Clinical outcomes in adulthood. Pediatrics. 2010;126(1):e156-62.
50. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: Systematic review and meta-analysis. Gut. 2011;60(2):209-218.
51. Gudsoorkar VS, Quigley EMM. Emerging treatments for chronic constipation. Expert Opin Emerg Drugs. 2013;18(3):365-373.
52. Eswaran S, Guentner A, Chey WD. Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation. J Neurogastroenterol Motil. 2014;20 (2):141-151.
53. Thomas RH, Luthin DR. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: Focus on prosecretory agents. Pharmacotherapy. 2015;35(6):613-630.
54. Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies. World J Gastroenterol. 2014;20(27):8898-8909.
55. Diederen K, Mugie SM, Benninga MA. Efficacy and safety of prucalopride in adults and children with chronic constipation. Expert Opin Pharmacother. 2015;16(3):407-416.
56. Emmanuel A, Cools M, Vandeplassche L, et al. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: An integrated analysis. Am J Gastroenterol. 2014;109 (6):887-894.
57. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: A randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2012;24(11):999-e541.
58. Müller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22 (9):991-8, e255.
59. Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29 (3):315-328.
60. Tack J, Van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58 (3):357-365.
61. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344-2354.
62. Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110 (5):741-748.
63. Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebocontrolled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil. 2015;27 (6):805-815.
64. Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57(2):197-203.
65. Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014;147 (6):1285-95.e1.
66. Mozaffari S, Didari T, Nikfar S, et al. Phase II drugs under clinical investigation for the treatment of chronic constipation. Expert Opin Investig Drugs. 2014;23(11):1485-1497.
67. Fukudo S, Hongo M, Kaneko H, et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: A randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23 (6):544-e205.
68. Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55(4):1090-1097.
69. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341.
70. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;27(8):685-696.
71. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170-177.
72. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351-1361.
73. Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol. 2015;13(2):294-301.e5.
74. Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587-599.
75. Hyman PE, Di Lorenzo C, Prestridge LL, et al. Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2014;58 (3):283-291.
76. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139(6):1877-1886.e2.
77. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138(3):886-95.e1.
78. Quigley EMM, Tack J, Chey WD, et al. Randomised clinical trials: Linaclotide phase 3 studies in IBS-C-a prespecified further analysis based on European medicines agency-specified endpoints. Aliment Pharmacol Ther. 2013;37(1):49-61.
79. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527-536.
80. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714-24; quiz p.1725.
81. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107 (11):1702-1712.
82. Love BL, Johnson A, Smith LS. Linaclotide: A novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm. 2014;71 (13):1081-1091.
83. Parker CH, Yuan Y, Liu LWC. Linaclotide: A new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. Clin Med Insights Gastroenterol. 2013;6:21-32.
84. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58 (9):2580-2586.
85. Hofmann AF, Loening-Baucke V, Lavine JE, et al. Altered bile acid metabolism in childhood functional constipation: Inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr. 2008;47(5):598-606.
86. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: A pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139 (5):1549-58, 1558.e1.
87. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8(2):159-165.
88. Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106(12):2154-2164.
89. Acosta A, Camilleri M, Kolar G, et al. Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2015. [Epub ahead of print].DOI:10.1016/j.cgh.2015.04.184.
90. Pacilli M, Pallot D, Andrews A, et al. Use of Peristeen® transanal colonic irrigation for bowel management in children: A single-center experience. J Pediatr Surg. 2014;49(2):269-72; discussion 272.
91. Choi EK, Han SW, Shin SH, et al. Longterm outcome of transanal irrigation for children with spina bifida. Spinal Cord. 2014;53(3):216-220.
92. Marte A, Borrelli M. Transanal irrigation and intestinal transit time in children with myelomeningocele. Minerva Pediatr. 2013;65(3):287-293.
93. Choi EK, Shin SH, Im YJ, et al. The effects of transanal irrigation as a stepwise bowel management program on the quality of life of children with spina bifida and their caregivers. Spinal Cord. 2013;51(5):384-388.
94. Corbett P, Denny A, Dick K, et al. Peristeen integrated transanal irrigation system successfully treats faecal incontinence in children. J Pediatr Urol. 2014;10(2):219-222.
95. Alenezi H, Alhazmi H, Trbay M, et al. Peristeen anal irrigation as a substitute for the MACE procedure in children who are in need of reconstructive bladder surgery. Can Urol Assoc J. 2014;8(1-2):E12-5.
96. Märzheuser S, Grauel F, Rothe K. [Treatment for fecal incontinence in patients with anorectal malformations. Introduction of a therapeutic approach]. Pflege Z. 2013;66(10):612-615.
97. Nasher O, Hill RE, Peeraully R, et al. Peristeen (©) transanal irrigation system for paediatric faecal incontinence: A single centre experience. Int J Pediatr. 2014;2014:954315.
98. Bischoff A, Levitt MA, Pena A. Bowel management for the treatment of pediatric fecal incontinence. Pediatr Surg Int. 2009;25(12):1027-1042.
99. King SK, Sutcliffe JR, Southwell BR, et al. The antegrade continence enema successfully treats idiopathic slow-transit constipation. J Pediatr Surg. 2005;40 (12):1935-1940.
100. Chatoorgoon K, Pena A, Lawal T, et al. Neoappendicostomy in the management of pediatric fecal incontinence. J Pediatr Surg. 2011;46(6):1243-1249.
101. Lawal TA, Rangel SJ, Bischoff A, et al. Laparoscopic-assisted Malone appendicostomy in the management of fecal incontinence in children. J Laparoendosc Adv Surg Tech. 2011;21(5):455-459.
102. Siminas S, Losty PD. Current surgical management of pediatric idiopathic constipation: A systematic review of published studies. Ann Surg. 2015. [Epub ahead of print]. DOI:10.1097/SLA.0000000000001191.
103. Hutson JM, Dughetti L, Stathopoulos L, et al. Transabdominal electrical stimulation (TES) for the treatment of slowtransit constipation (STC). Pediatr Surg Int. 2015;31(5):445-451.
104. Clarke MCC, Chase JW, Gibb S, et al. Decreased colonic transit time after transcutaneous interferential electrical stimulation in children with slow transit constipation. J Pediatr Surg. 2009;44 (2):408-412.
105. Chase J, Robertson VJ, Southwell B, et al. Pilot study using transcutaneous electrical stimulation (interferential current) to treat chronic treatment-resistant constipation and soiling in children. J Gastroenterol Hepatol. 2005;20(7):1054-1061.
106. Clarke MCC, Catto-Smith AG, King SK, et al. Transabdominal electrical stimulation increases colonic propagating pressure waves in paediatric slow transit constipation. J Pediatr Surg. 2012;47 (12):2279-2284.
107. Yik YI, Clarke MCC, Catto-Smith AG, et al. Slow-transit constipation with concurrent upper gastrointestinal dysmotility and its response to transcutaneous electrical stimulation. Pediatr Surg Int. 2011;27(7):705-711.
108. Clarke MCC, Chase JW, Gibb S, et al. Improvement of quality of life in children with slow transit constipation after treatment with transcutaneous electrical stimulation. J Pediatr Surg. 2009;44 (6):1268-72; discussion 1272.
109. Leong LCY, Yik YI, Catto-Smith AG, et al. Long-term effects of transabdominal electrical stimulation in treating children with slow-transit constipation. J Pediatr Surg. 2011;46 (12):2309-2312.
110. Yik YI, Ismail KA, Hutson JM, et al. Home transcutaneous electrical stimulation to treat children with slow-transit constipation. J Pediatr Surg. 2012;47 (6):1285-1290.
111. Carrington EV, Evers J, Grossi U, et al. A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation. Neurogastroenterol Motil. 2014;26 (9):1222-1237.
112. Maeda Y, O'Connell PR, Lehur P-A, et al. Sacral nerve stimulation for faecal incontinence and constipation: A European consensus statement. Colorectal Dis. 2015;17(4):O74-87.
113. Sulkowski JP, Nacion KM, Deans KJ, et al. Sacral nerve stimulation: A promising therapy for fecal and urinary incontinence and constipation in children. J Pediatr Surg. 2015;1-4. [Epub ahead of print].DOI:10.1016/j. jpedsurg.2015.03.043.
114. Ratto C, Ganio E, Naldini G. Long-term results following sacral nerve stimulation for chronic constipation. Colorectal Dis. 2015;17(4):320-328.
115. Dinning PG, Hunt L, Patton V, et al. Treatment efficacy of sacral nerve stimulation in slow transit constipation: A twophase, double-blind randomized controlled crossover study. Am J Gastroenterol. 2015;110(5):733-740.
116. Van Wunnik BP, Peeters B, Govaert B, et al. Sacral neuromodulation therapy: A promising treatment for adolescents with refractory functional constipation. Dis Colon Rectum. 2012;55(3):278-285.
117. Levitt MA, Mathis KL, Pemberton JH. Surgical treatment for constipation in children and adults. Best Pract Res Clin Gastroenterol. 2011;25(1):167-179.
118. Eradi B, Hamrick M, Bischoff A, et al. The role of a colon resection in combination with a Malone appendicostomy as part of a bowel management program for the treatment of fecal incontinence. J Pediatr Surg. 2013;48 (11):2296-2300.
119. Rutten JMTM, Reitsma JB, Vlieger AM, et al. Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: A systematic review. Arch Dis Child. 2013;98(4):252-257.
120. Rutten JMTM, Korterink JJ, Venmans LMAJ, et al. Nonpharmacologic treatment of functional abdominal pain disorders: A systematic review. Pediatrics. 2015;135(3):522-535.
121. Aucoin M, Lalonde-Parsi MJ, Cooley K. Mindfulness-based therapies in the treatment of functional gastrointestinal disorders: A meta-analysis. Evid Based Complement Alternat Med. 2014;2014:140724.
122. Rossen NG, MacDonald JK, De Vries EM, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol. 2015;21(17):5359-5371.
123. Sha S, Liang J, Chen M, et al. Systematic review: Faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther. 2014;39(10):1003-1032.
124. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475-483.
125. Ron Y, Halpern Z, Safadi R, et al. Safety and efficacy of the vibrating capsule, an innovative non-pharmacological treatment modality for chronic constipation. Neurogastroenterol Motil. 2015;27 (1):99-104.
126. Liem O, Harman J, Benninga M, et al. Health utilization and cost impact of childhood constipation in the United States. J Pediatr. 2009;154(2):258-262.
127. Kuizenga-Wessel S, Benninga MA, Tabbers MM. Reporting outcome measures of functional constipation in children from 0 to 4 years of age. J Pediatr Gastroenterol Nutr. 2015;60 (4):446-456.
128. Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166(1):85-90.
129. Varni JW, Bendo CB, Shulman RJ, et al. Interpretability of the PedsQLTM gastrointestinal symptoms scales and gastrointestinal worry scales in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr Psychol. 2015;40(6):591-601.
130. Silverman AH, Berlin KS, Di Lorenzo C, et al. Measuring health-related quality of life with the parental opinions of pediatric constipation questionnaire. J Pediatr Psychol. 2015;40(8):814-824.